![]() |
---|
You can evaluate the efficacy and safety of drug candidates and functional materials more accurately, efficiently and quickly at lower cost than ever. Human myeloid linage cells (one of white blood cells) stably supplied at low cost through cutting-edge technologies will increase the efficiency of the development of drugs and functional materials in future.
Mylc, human myeloid
linage cells,
changes the research
of drugs and materials.
PRODUCTS
Our products are high precision immature blood cells,
which accelerate various types of evaluation and research of drugs and functional materials.
Kit products, which contain a set of the necessary items for evaluation, are also available.

Differentiated state (condition) of blood cells and our products

You can select our blood cells and how they are provided from among various options depending on the research objectives.


High precision homogeneous blood cells with identical genetic information perfectly meet R&D demands.
Homogeneous blood cells
with identical genetic
information
We can control the
differentiation stage to
the optimum conditions
Stable mass-production
and supply are possible
The same genetic information and conditions can be always reproduced in our laboratory. This feature contributes to a drastic improvement in the accuracy and applicability of evaluation.
Differentiation stage (maturity) can be minutely controlled with our high level of regenerative medicine technologies and product control. Research and evaluation of high accuracy are available.
You can obtain blood cells in the sufficient quantities in ideal condition any time. You can conduct research and development and efficacy evaluation with no delay and accelerate your development.

Mylc cells
(immature dendritic cells)
Uniform differentiation stage and highly homogeneous
High precision results standing out from evaluation using conventional blood cells.You can also reduce your cost.
Dendritic cells are a key factor for evaluation. It used to be almost impossible to extract pure dendritic cells from provided blood. However, now we can mass-produce them stably in an immature state using iPS cell technology. Thus, the precision of evaluation has been drastically improved compared with that using conventional blood cells and the cost and the time can be greatly reduced.
Blood cells of MiCAN
-
Can be always stably provided in uninfected, non-stimulated condition.
-
Very high sensitivity to virus infection.
-
Highly reliable evaluation results by the homogeneous and pure blood cells.
-
The optimum condition and type for evaluation can be selected and controlled.
-
Blood cells with the same genetic information are always obtainable.
-
Quick procedure from production of blood cells through acquisition of evaluation results.

Monkey-derived blood cells
-
Reproducibility in humans is unclear because they are not human-derived.
-
Sensitivity to human-infecting viruses is low.
Red cross-provided blood
-
Difficult to obtain sufficient blood packs, which would cause delay in research.
-
Percentage of usable dendritic cells is 0.1% or less.
-
Pure extraction of dendritic cells is impossible.
-
Inter-pack variability in conditions is large, resulting in low reliability in evaluation.
-
Impossible to obtain blood cells in the same conditions again.

immature
dendritic cells
Mylc
The cells are dendritic cells of high precision and high sensitivity, realized using iPS cell technology (regenerative medicine technology). Their differentiation state is controlled to remain in an immature state (non-stimulated). Substituting provided blood, which has many problems, such as variable condition and poor availability, our products can drastically improve the reliability and speed of various evaluations of drugs and functional materials. A variety of cells with different genetic background can be produced. Our products are the most suitable for research of infectious diseases.
Mylc’s high sensitivity and accurate results strongly drives research of infectious diseases
Mylc strongly supports research with high sensitivity to infection and accurate results compared with conventional research materials.
Comparison of sensitivity to infection

Three different types of the genetic backgrounds to meet demands.
You can select the base cells (3 types) and genotype of white blood cells (HLA, etc.).
You can also customize the cells from provided blood (uMylc).
aMylc
Human peripheral blood mononuclear cells
Showing in vivo-like characteristics and reactions
iMylc
iPS cell-derived blood cells
Having standardized genetic background. Standard reactions can be elicited.
uMylc
Customization
using provided blood
Blood cell materials with characteristics of the donor can be prepared.
Evaluation kit
Mylc ELISA(human IL-6) Kit

Evaluation kit using Mylc cells, which are excellent in precision and reproducibility. This kit contains the key materials and the evaluation conditions have already been optimized. Evaluation using cells which you are not familiar with is often troublesome, but you can start evaluation quickly with this kit optimized for evaluation.
Assay protocol is already fixed.
You can start evaluation studies immediately.

Contents of kit
Cells : Mylc cells (frozen in storage medium, 1 screw vial)
Specific culture medium : Specific for culture of Mylc cells for measurement and evaluation (frozen product, 50 mL bottle × 1)
Stimulant : NiSO4 solution for control stimulation (refrigerated, 1 vial)
Measurement reagent : ELISA kit for measurement of IL-6 produced in supernatant
You can obtain the results the day following the evaluation.
This speed greatly accelerates research and development.
You can readily perform high quality evaluation.
You can readily use a large quantity of homogeneous Mylc cells for evaluation without troublesome condition setting.
Free from complicated condition setting
Because the kit is delivered with the optimum conditions for evaluation, you can readily start evaluation.
You can start immediately with this All-in-One kit.
This kit contains all the materials necessary for evaluation: from blood cells to measurement reagents. You can start evaluation immediately.
Principle of evaluation
A test substance is added to the Mylc cells, and the produced transmitter (IL-6) is quantified. The intensity of the stimulation by the test substance can be evaluated numerically, which enables judgment of the function.

*Please provide the following instruments and materials by yourself in advance.
Sterilized centrifuge tubes/Pipettes and pipette tips/96-well culture plate /
Centrifuge, CO2 incubator/other necessary materials and instruments

Red blood cells
Mpv
The percentage of juvenile red blood cells (immediate precursors of erythrocytes), which are necessary for research of malaria, in blood is very small, and the poor availability has hampered research. Our juvenile red blood cells optimized for research, produced by regenerative medicine technology, strongly drive the research of malaria.

Malaria infects red blood cells only at a specific stage (precursors of erythrocytes). It used to be very difficult to obtain these blood cells suitable for infection experiments from conventional provided blood. Mpv cells consist of pure red blood cells and it was confirmed that malaria easily infects them.
Phenocell is a research-based R&D company specialized in the design of phenotypic assays for research and drug discovery using iPSC-derived somatic cells.
Phenocell and MiCAN is going to collaborate of new evaluation systems and products.
Original iPS cell line
Caucasian, Asian, African






iMylc-PhC1
(Immature dendritic cells)
PIPELINE
We are developing different types of myeloid blood cells for different purposes including those for COVID-19. We have newly started the development of macrophage lineage blood cells.
Mpv series / Vivax Malaria research / Mpv-02 FY 2021 Cell providing start
Mylc series / Drug discovery research / Mylc-03 FY2020 Evaluation kit launch
Mylc series / COVID-19 research / cMylc FY2020 Cell kit launch
Mylc series / Infection research(Universal) / Mylc-05 FY2022 Cell launch
Other / Functional material research / Mfc-01 FY2023 Cell launch